Mechanisms underlying the immunosuppressive microenvironment in hepatocellular carcinoma (HCC) extend beyond immune checkpoints to include metabolic competition. Here, we identify a metabolic evasion pathway driven by SLC1A5 overexpression, which enables HCC cells to sequester glutamine from the tumor microenvironmen...
Jingjing Nian, Zi-Ran Wang, Shi-Yi Chen et al.· Cell Death & Disease· 0 citations
PURPOSE
To develop a non-invasive, urine-based approach for dynamic monitoring of tumor burden and early detection of recurrence in hepatocellular carcinoma (HCC), addressing the limited sensitivity of conventional serum biomarkers such as AFP and DCP, particularly for minimal residual disease (MRD) assessment.
METHO...
Xiao-Hua Xing, En Hu, Lei Song et al.· Molecular & Cellular Proteom...· 0 citations
Lenvatinib is approved as a first-line treatment for patients with unresectable hepatocellular carcinoma (HCC), however, its clinical efficacy is frequently limited by the emergence of drug resistance. This study aimed to elucidate the underlying mechanisms by which HCC develops resistance to lenvatinib. Lenvatinib-res...
Niangmei Cheng, Kexin Liu, Xin Qi et al.· Molecular and Cellular Bioch...· 0 citations
Hepatocellular carcinoma is one of the most common malignant tumors with poor clinical outcomes. Increasing numbers of long noncoding RNAs have been shown to be involved in the carcinogenesis and progression of HCC. However, the expressions, clinical significances, and roles of most lncRNAs in HCC are still unknown. In...
Fei Wang, Ji-Zhe Liu, Gaoxiong Wang et al.· Scientific Reports· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
